Matthew Randolph Lee

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 18(Granted Patents)

Location History:

San Diego, CA (US) (2022)
Del Mar, CA (US) (2019 - 2024)

Company Filing History:

7 out of 38

Mirati Therapeutics, Inc.

patents

3 out of 3

Cervello Therapeutics, Llc.

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

2. 11932633 - KRas G12C inhibitors (2024-03-19),

3. 11912719 - Substituted isoquinolines as rock kinase inhibitors (2024-02-27),

4. 11485738 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-11-01),

5. 11267812 - KRAS G12C inhibitors (2022-03-08),

6. 11248004 - Substituted isoquinolines as rock kinase inhibitors (2022-02-15),

7. 11220509 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-01-11),

8. 11091495 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2021-08-17),

9. 10745381 - Substituted isoquinolines and phthalazines as rock kinase inhibitors (2020-08-18),

10. 10266542 - EZH2 inhibitors (2019-04-23),

Title: The Innovative Mind of Matthew Randolph Lee

Introduction

Matthew Randolph Lee is an accomplished inventor based in Del Mar, California. With a total of nine patents to his name, he has significantly contributed to the fields of pharmaceuticals and biotechnology. His latest inventions focus on advancing treatments for serious health conditions through powerful mechanisms of action.

Latest Patents

Among his groundbreaking patents, one notable innovation involves KRas G12C inhibitors. This invention encompasses compounds that irreversibly inhibit the activity of the KRas G12C protein. The potential applications of these compounds extend to pharmaceutical compositions and methods that offer new hope for patients affected by cancers driven by this mutation.

Another key patent introduced by Matthew involves substituted isoquinolines as Rho-associated protein kinase (ROCK) inhibitors. This invention highlights indoline-based compounds designed to inhibit ROCK activity, with therapeutic implications for treating cerebral cavernous malformation syndrome (CCM) and various cardiovascular diseases. The versatility and potential impact of these compounds illustrate Lee's dedication to addressing critical medical challenges.

Career Highlights

Matthew Randolph Lee has worked with prominent companies such as Mirati Therapeutics, Inc. and Cervello Therapeutics, LLC. His experiences in these leading firms have helped foster an environment of innovation, enabling the development of groundbreaking therapies aimed at improving patients’ lives.

Collaborations

Throughout his career, Lee has collaborated with notable professionals in the industry, including Matthew Arnold Marx and Thomas P Bobinski. These partnerships have allowed for the exchange of ideas and expertise, further enhancing the innovative capabilities of his projects.

Conclusion

In summary, Matthew Randolph Lee stands out as a prolific inventor whose contributions are pivotal to advancements in medical science. With his array of patents, he showcases a commitment to innovation that addresses pressing health concerns. As his career continues to evolve, the impact of his inventions is certain to resonate within the fields of pharmaceuticals and biotechnology.

This text is generated by artificial intelligence and may not be accurate.